Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, ...

Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination. For pharmacists counseling patients this ...

A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

BioNTech (BNTX) ADRs lost ~5% in the premarket on Thursday after Bloomberg News reported that Pfizer (PFE) is planning to sell its remaining stake in its partner, which helped the U.S. pharma giant to ...

A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna ...

The deal comes as BioNTech works to complete the $1.25 billion acquisition of CureVac that it announced in June. (Avosb/iStock/Getty Images Plus) The chapter on Pfizer and BioNTech’s mRNA patent feud ...

Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming ...

London's Court of Appeal on Friday struck down a case filed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), in a bid to reverse a prior High Court ruling that granted a patent win to their rival ...